A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Status:
Suspended
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and
Flt3. Phase I study has shown that the toxicity is manageable.
The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in
patients with Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Collaborators:
Shanghai Pulmonary Hospital, Shanghai, China Sun Yat-sen University